CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH

CWA Asset Management Group LLC purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,096 shares of the medical equipment provider’s stock, valued at approximately $1,670,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Stanley Laman Group Ltd. boosted its holdings in Lantheus by 38.7% in the 3rd quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock worth $4,087,000 after buying an additional 22,229 shares during the period. Quantbot Technologies LP purchased a new stake in Lantheus in the 3rd quarter worth $1,847,000. American Assets Inc. bought a new stake in Lantheus during the third quarter valued at about $872,000. Campbell & CO Investment Adviser LLC bought a new stake in Lantheus during the third quarter valued at about $2,184,000. Finally, Assetmark Inc. lifted its position in shares of Lantheus by 20.1% in the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after acquiring an additional 19,844 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Lantheus stock opened at $76.43 on Monday. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $108.91. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The firm’s fifty day moving average is $71.53 and its 200 day moving average is $62.65. The company has a market cap of $4.98 billion, a price-to-earnings ratio of 22.68 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business’s revenue was up 4.0% on a year-over-year basis. During the same period last year, the company posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Wall Street Zen cut Lantheus from a “strong-buy” rating to a “buy” rating in a report on Sunday, March 15th. Truist Financial upped their price target on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $110.00 price objective on shares of Lantheus in a research report on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $86.14.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.